Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer Care

News
Podcast

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Episode Highlights

0:04 - Intro

0:37 - ESMO 2023 Presentation on Dato-DXd in NSCLC

1:15 - Methods/Design of TROPION-Lung01

2:35 - Efficacy End Points

4:20 - Questions on Actionable Genomic Alterations

4:59 - Overall Survival Analyses

5:53 - Safety Findings

7:45 - ILD Events

8:45 - Overview of Findings

10:14 - Takeaways for Community Oncologists

12:42 - Next Steps for Dato-DXd

15:14 - Closing Thoughts

In season 4, episode 20 of Targeted Talks, Aaron Lisberg, MD, a thoracic medical oncologist at the University of California, Los Angeles (UCLA), delves into findings from the phase 3 TROPION-Lung01 study (NCT04656652) of datopotamab deruxtecan (Dato-DXd; DS-1062a) for the treatment of patients with advanced or metastatic non–small cell lung cancer (NSCLC).

Dato-DXd is a Trop-2 directed antibody drug conjugate. In the phase 3, open-label, global study, Dato-DXd was compared with docetaxel for the treatment of this patient population. Patients were randomly assigned in a 1:1 fashion to receive Dato-DXd 6 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks.

According to findings presented at the 2023 ESMO Congress, Dato-DXd led to a statistically significant improvement in progression-free survival (PFS) for the treatment of patients with advanced or metastatic NSCLC. However, patients with squamous histology did not experience a benefit, suggesting differences in how these cancer types respond to this treatment.

Although TROPION-Lung01 revealed a PFS advantage among patients with non-squamous lung cancer, the occurrence of grade 3 or higher interstitial lung disease (ILD) highlights the importance of cautious monitoring and strict adherence to ILD management guidelines for all patients receiving this Dato-DXd.

“The take home here was that Dato-DXd was a better tolerated drug from a global perspective, although there are some clear differences in terms of toxicity profile. It appears to be a potential new, meaningful therapy for patients with non-squamous metastatic advanced non–small cell lung cancer eligible for second-line chemotherapy,” said Lisberg.

Overall, the TROPION-Lung01 data suggest that non-squamous histology might be a key predictor of response to this therapy. Further research is needed to understand this disparity and tailor treatment strategies accordingly.

REFERENCE:

Ahn MJ, Lisberg A, Paz-Ares L, et al. Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of the randomized phase 3 study TROPION-Lung01. Ann Oncol. 2023;34(suppl 2):S1305-S1306. doi:10.1016/j.annon
Related Videos
Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer
Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer
Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer
Related Content